The rule would revise various aspects of NRC’s regulations, including:
- Updates to training and experience requirements for authorized users, medical physicists, radiation safety officers (RSOs) and nuclear pharmacists;
- Changes to the definition of reportable “medical events” in permanent implant brachytherapy;
- Implementation of the ACR-supported petition to recognize the qualifications of board certified medical physicists and RSOs not specifically named on a license; and
- Many other items that have been vetted or requested by medical stakeholders in the years since Part 35 implementation in the early 2000s.
Last week at the fall ACMUI business meeting, clinical oncologists who spoke in support of the industry request indicated that these therapies are not preferred because their residents are not trained for them and because oncologists prefer to maintain direct control over treatments instead of referring their patients to other specialists for therapy.
In response to the industry request, which is specific to alpha- and beta-emitters, the NRC ACMUI intends to revisit all training and experience requirements in the NRC’s medical use regulations over the next several years. In the meantime, the American College of Radiology, American Society for Radiation Oncology, Society of Nuclear Medicine and Molecular Imaging and others in the medical community are requesting that the final rule currently under Commission review advance as quickly as possible to address the more thoroughly vetted needs of the medical community.